22.88MMarket Cap17.50P/E (TTM)
0.764High0.700Low9.36KVolume0.700Open0.700Pre Close6.66KTurnover0.05%Turnover RatioLossP/E (Static)32.69MShares2.61052wk High3.15P/B12.22MFloat Cap0.62152wk Low--Dividend TTM17.46MShs Float9.800Historical High--Div YieldTTM9.08%Amplitude0.621Historical Low0.711Avg Price1Lot Size
ProMIS Neurosciences Stock Forum
ProMIS Neurosciences Showcases Preclinical Data on Platform-Derived Antibody and Vaccines for Neurodegenerative Diseases at Alzheimer's Disease/Parkinson's Disease 2025 International Conference
Monday, 24th March at 7:00 am
CAMBRIDGE, Massachusetts, March 24, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misf...
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer's Disease
5 minutes ago, 4:00 AM PST
Via GlobeNewswire
PMN
Share
CAMBRIDGE, Massachusetts, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b clinical trial (PRECISE-AD) evaluating its lead therapeutic...
$Ascent Solar Technologies (ASTI.US)$- Following delivery and the successful completion of the on-orbi...
director bought around 200k shares at average of 1.28!
ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences
ProMIS Neurosciences (Nasdaq: PMN) will present preclinical data on its lead product candidate, PMN310, at the 4th International Conference on Cognitive & Behavioral Neurosciences. The data supports PMN310's potential as an Alzheimer's dise...
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
ProMIS Neurosciences Inc. (Nasdaq: PMN) presented preclinical data at the 2024 Alzheimer's Association International Conference (AAIC) supporting their novel approach to optimizing an Alzheimer's disease (AD) vaccine. The company's proprietary computational platform identified four AβO-restricte...
No comment yet